PortfoliosLab logoPortfoliosLab logo
MTUAY vs. VRNA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MTUAY vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MTU Aero Engines AG (MTUAY) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


MTUAY

1D
0.01%
1M
8.73%
YTD
-12.05%
6M
-11.53%
1Y
-6.93%
3Y*
14.44%
5Y*
8.41%
10Y*
16.24%

VRNA

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

MTUAY vs. VRNA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MTUAY
MTU Aero Engines AG
-12.05%26.67%54.85%1.39%7.65%-21.51%-8.19%63.25%1.46%33.20%
VRNA
Verona Pharma plc
0.00%130.21%133.60%-23.92%288.84%-4.00%21.74%-40.41%-18.71%-12.07%

Correlation

The correlation between MTUAY and VRNA is -0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

-0.04

Correlation (3Y)
Calculated over the trailing 3-year period

0.08

Correlation (5Y)
Calculated over the trailing 5-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Apr 27, 2017

0.11

The correlation between MTUAY and VRNA shifts across timeframes, from -0.04 (1 year) to 0.11 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

MTUAY:

$19.62B

VRNA:

$9.72B

EPS

MTUAY:

€16.10

VRNA:

-$0.69

PS Ratio

MTUAY:

1.08

VRNA:

57.97

PB Ratio

MTUAY:

3.93

VRNA:

34.92

Total Revenue (TTM)

MTUAY:

€15.80B

VRNA:

$167.65M

Gross Profit (TTM)

MTUAY:

€3.02B

VRNA:

$159.52M

EBITDA (TTM)

MTUAY:

€2.53B

VRNA:

-$40.86M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MTUAY vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MTUAY
MTUAY Risk / Return Rank: 3131
Overall Rank
MTUAY Sharpe Ratio Rank: 3232
Sharpe Ratio Rank
MTUAY Sortino Ratio Rank: 2929
Sortino Ratio Rank
MTUAY Omega Ratio Rank: 2929
Omega Ratio Rank
MTUAY Calmar Ratio Rank: 3535
Calmar Ratio Rank
MTUAY Martin Ratio Rank: 3232
Martin Ratio Rank

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MTUAY vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MTU Aero Engines AG (MTUAY) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MTUAYVRNADifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

0.99

Calmar ratioReturn relative to maximum drawdown

-0.26

Martin ratioReturn relative to average drawdown

-0.60

MTUAY vs. VRNA - Sharpe Ratio Comparison


Loading charts...

Drawdowns

MTUAY vs. VRNA - Drawdown Comparison


Loading charts...

Drawdown Indicators


MTUAYVRNADifference

Max Drawdown

Largest peak-to-trough decline

-64.31%

Max Drawdown (1Y)

Largest decline over 1 year

-32.62%

Max Drawdown (3Y)

Largest decline over 3 years

-34.69%

Max Drawdown (5Y)

Largest decline over 5 years

-43.53%

Max Drawdown (10Y)

Largest decline over 10 years

-64.31%

Current Drawdown

Current decline from peak

-22.93%

Average Drawdown

Average peak-to-trough decline

-12.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.88%

Volatility

MTUAY vs. VRNA - Volatility Comparison


Loading charts...

Volatility by Period


MTUAYVRNADifference

Volatility (1M)

Calculated over the trailing 1-month period

11.82%

Volatility (6M)

Calculated over the trailing 6-month period

28.59%

Volatility (1Y)

Calculated over the trailing 1-year period

33.99%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

32.31%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

35.69%

Dividends

MTUAY vs. VRNA - Dividend Comparison

MTUAY's dividend yield for the trailing twelve months is around 1.17%, while VRNA has not paid dividends to shareholders.


PositionTTM2025202420232022202120202019201820172016
MTUAY
MTU Aero Engines AG
1.17%0.60%0.66%1.63%1.07%0.73%1.02%0.79%1.11%1.85%2.87%
VRNA
Verona Pharma plc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

MTUAY vs. VRNA - Financials Comparison

This section allows you to compare key financial metrics between MTU Aero Engines AG and Verona Pharma plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B20212022202320242025
4.53B
75.14M
(MTUAY) Total Revenue
(VRNA) Total Revenue
Please note, different currencies. MTUAY values in EUR, VRNA values in USD

MTUAY vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between MTU Aero Engines AG and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%100.0%20212022202320242025
18.8%
95.4%
Portfolio components
MTUAY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, MTU Aero Engines AG reported a gross profit of 853.63M and revenue of 4.53B. Therefore, the gross margin over that period was 18.8%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

MTUAY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, MTU Aero Engines AG reported an operating income of 620.37M and revenue of 4.53B, resulting in an operating margin of 13.7%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

MTUAY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, MTU Aero Engines AG reported a net income of 512.18M and revenue of 4.53B, resulting in a net margin of 11.3%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.


Frequently Asked Questions


MTUAY and VRNA have a correlation of -0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for MTUAY and VRNA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer